Ovarian cancer bispecific antibody therapeutic - Immune Biosolutions
Latest Information Update: 08 Feb 2023
At a glance
- Originator Immune Biosolutions
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Ovarian cancer
Most Recent Events
- 11 Jan 2023 Early research in Ovarian cancer in Canada (Parenteral) prior to January 2023 (Immune BioSolutions pipeline, January 2023)